{
 "drug": "Irinotecan Hydrochloride Injection",
 "asOf": "2026-08-25",
 "status": "discontinuing",
 "since": "09/26/2025",
 "dayN": 333,
 "cat": "Oncology",
 "companies": [
  "Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)",
  "Ingenus Pharmaceuticals LLC"
 ],
 "reasons": [],
 "records": [
  {
   "discontinued_date": "09/26/2025",
   "update_type": "New",
   "initial_posting_date": "09/26/2025",
   "package_ndc": "25021-230-05",
   "generic_name": "Irinotecan Hydrochloride Injection",
   "contact_info": "Company Contact: 609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)",
   "related_info": "Discontinuation of the manufacture of the drug; Distributed by Sagent Pharmaceuticals",
   "openfda": {
    "application_number": [
     "ANDA090675"
    ],
    "brand_name": [
     "IRINOTECAN HYDROCHLORIDE"
    ],
    "generic_name": [
     "IRINOTECAN HYDROCHLORIDE"
    ],
    "manufacturer_name": [
     "Sagent Pharmaceuticals"
    ],
    "product_ndc": [
     "25021-230"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRAVENOUS"
    ],
    "substance_name": [
     "IRINOTECAN HYDROCHLORIDE"
    ],
    "rxcui": [
     "1726319",
     "1726324"
    ],
    "spl_id": [
     "beff4b0b-e884-4134-ba9e-290020a94add"
    ],
    "spl_set_id": [
     "caab50e6-0dad-4ddd-9a6c-96cc2b87aee7"
    ],
    "package_ndc": [
     "25021-230-02",
     "25021-230-05"
    ],
    "unii": [
     "042LAQ1IIS"
    ]
   },
   "update_date": "09/26/2025",
   "therapeutic_category": [
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Irinotecan Hydrochloride, Injection, 100 mg/5 mL (NDC 25021-230-05)",
   "company_name": "Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "02/24/2026",
   "update_type": "New",
   "initial_posting_date": "02/24/2026",
   "package_ndc": "50742-401-02",
   "generic_name": "Irinotecan Hydrochloride Injection",
   "contact_info": "866-321-5031",
   "related_info": "A business decision was made to discontinue manufacture of the drug.",
   "openfda": {
    "application_number": [
     "ANDA206935"
    ],
    "brand_name": [
     "IRINOTECAN HYDROCHLORIDE"
    ],
    "generic_name": [
     "IRINOTECAN HYDROCHLORIDE"
    ],
    "manufacturer_name": [
     "Ingenus Pharmaceuticals, LLC"
    ],
    "product_ndc": [
     "50742-401",
     "50742-402"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRAVENOUS"
    ],
    "substance_name": [
     "IRINOTECAN HYDROCHLORIDE"
    ],
    "rxcui": [
     "1726319",
     "1726324"
    ],
    "spl_id": [
     "b3cfa0f6-fbdc-4f19-9dac-beaf398603d8"
    ],
    "spl_set_id": [
     "d04f2471-3085-4fc8-a657-bb3918d48e6e"
    ],
    "package_ndc": [
     "50742-401-02",
     "50742-402-05"
    ],
    "unii": [
     "042LAQ1IIS"
    ]
   },
   "update_date": "02/24/2026",
   "therapeutic_category": [
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Irinotecan Hydrochloride, Injection, 40 mg/2 mL (NDC 50742-401-02)",
   "company_name": "Ingenus Pharmaceuticals LLC",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "09/26/2025",
   "update_type": "New",
   "initial_posting_date": "09/26/2025",
   "package_ndc": "25021-230-02",
   "generic_name": "Irinotecan Hydrochloride Injection",
   "contact_info": "Company Contact: 609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)",
   "related_info": "Discontinuation of the manufacture of the drug; Distributed by Sagent Pharmaceuticals",
   "openfda": {
    "application_number": [
     "ANDA090675"
    ],
    "brand_name": [
     "IRINOTECAN HYDROCHLORIDE"
    ],
    "generic_name": [
     "IRINOTECAN HYDROCHLORIDE"
    ],
    "manufacturer_name": [
     "Sagent Pharmaceuticals"
    ],
    "product_ndc": [
     "25021-230"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRAVENOUS"
    ],
    "substance_name": [
     "IRINOTECAN HYDROCHLORIDE"
    ],
    "rxcui": [
     "1726319",
     "1726324"
    ],
    "spl_id": [
     "beff4b0b-e884-4134-ba9e-290020a94add"
    ],
    "spl_set_id": [
     "caab50e6-0dad-4ddd-9a6c-96cc2b87aee7"
    ],
    "package_ndc": [
     "25021-230-02",
     "25021-230-05"
    ],
    "unii": [
     "042LAQ1IIS"
    ]
   },
   "update_date": "09/26/2025",
   "therapeutic_category": [
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Irinotecan Hydrochloride, Injection, 40 mg/2 mL (NDC 25021-230-02)",
   "company_name": "Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "02/24/2026",
   "update_type": "New",
   "initial_posting_date": "02/24/2026",
   "package_ndc": "50742-402-05",
   "generic_name": "Irinotecan Hydrochloride Injection",
   "contact_info": "866-321-5031",
   "related_info": "A business decision was made to discontinue manufacture of the drug.",
   "openfda": {
    "application_number": [
     "ANDA206935"
    ],
    "brand_name": [
     "IRINOTECAN HYDROCHLORIDE"
    ],
    "generic_name": [
     "IRINOTECAN HYDROCHLORIDE"
    ],
    "manufacturer_name": [
     "Ingenus Pharmaceuticals, LLC"
    ],
    "product_ndc": [
     "50742-402",
     "50742-401"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRAVENOUS"
    ],
    "substance_name": [
     "IRINOTECAN HYDROCHLORIDE"
    ],
    "rxcui": [
     "1726319",
     "1726324"
    ],
    "spl_id": [
     "b3cfa0f6-fbdc-4f19-9dac-beaf398603d8"
    ],
    "spl_set_id": [
     "d04f2471-3085-4fc8-a657-bb3918d48e6e"
    ],
    "package_ndc": [
     "50742-401-02",
     "50742-402-05"
    ],
    "unii": [
     "042LAQ1IIS"
    ]
   },
   "update_date": "02/24/2026",
   "therapeutic_category": [
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Irinotecan Hydrochloride, Injection, 100 mg/5 mL (NDC 50742-402-05)",
   "company_name": "Ingenus Pharmaceuticals LLC",
   "status": "To Be Discontinued"
  }
 ]
}